Why the study?
Does amiodarone affect mortality in patients with chronic congestive heart failure?
Does amiodarone affect mortality in patients with chronic congestive heart failure?
This editorial discusses the Veterans Affairs Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure, which evaluated the effect of amiodarone on mortality in patients with chronic heart failure.
Two recent studies have suggested that amiodarone, a potent antiarrhythmic agent, is a promising drug for the treatment of ventricular tachyarrhythmias after myocardial infarction.1,2 The results of two additional studies of the use of amiodarone after myocardial infarction (the European Myocardial Infarct Amiodarone Trial and the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial) will soon be reported.3,4 In this issue of the Journal, Singh and his coworkers report the results of the Veterans Affairs Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure.5 This trial examined the effect of amiodarone on mortality in patients with chronic congestive heart failure . . .
No takes yet. Share an insight, caveat, or question.
Günter Breithardt (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: